Cancer Genetics Inc Q1 2018 Institutional Investor Sentiment Better Than Expected

June 21, 2018 - By Marie Mckinney

Cancer Genetics, Inc. (NASDAQ:CGIX) Logo

Sentiment for Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics Inc (NASDAQ:CGIX) institutional sentiment increased to 1.11 in Q1 2018. Its up 0.20, from 0.91 in 2017Q4. The ratio has increased, as 10 hedge funds increased or started new holdings, while 9 decreased and sold equity positions in Cancer Genetics Inc. The hedge funds in our partner’s database reported: 2.70 million shares, down from 2.78 million shares in 2017Q4. Also, the number of hedge funds holding Cancer Genetics Inc in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 3 Reduced: 6 Increased: 4 New Position: 6.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $27.47 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

The stock decreased 0.90% or $0.01 during the last trading session, reaching $0.99. About 5,521 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since June 21, 2017 and is downtrending. It has underperformed by 86.82% the S&P500.

Analysts await Cancer Genetics, Inc. (NASDAQ:CGIX) to report earnings on August, 13. They expect $-0.13 EPS, up 18.75 % or $0.03 from last year’s $-0.16 per share. After $-0.16 actual EPS reported by Cancer Genetics, Inc. for the previous quarter, Wall Street now forecasts -18.75 % EPS growth.

Perkins Capital Management Inc holds 1.43% of its portfolio in Cancer Genetics, Inc. for 963,600 shares. Diker Management Llc owns 64,365 shares or 0.04% of their US portfolio. Moreover, Granahan Investment Management Inc Ma has 0.03% invested in the company for 235,502 shares. The New York-based Hrt Financial Llc has invested 0.02% in the stock. Court Place Advisors Llc, a Maryland-based fund reported 10,000 shares.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Ratings analysis reveals 50% of Cancer Genetics’s analysts are positive. Out of 2 Wall Street analysts rating Cancer Genetics, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $300 while the high is $6.0. The stock’s average target of $4.50 is 354.55% above today’s ($0.99) share price. CGIX was included in 4 notes of analysts from January 16, 2018. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 16. The rating was downgraded by Maxim Group on Tuesday, April 3 to “Hold”. H.C. Wainwright maintained the shares of CGIX in report on Tuesday, May 29 with “Buy” rating. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) earned “Buy” rating by H.C. Wainwright on Tuesday, February 6.

More recent Cancer Genetics, Inc. (NASDAQ:CGIX) news were published by: which released: “Safirstein Metcalf LLP Reminds Investors That A Class Action Has Been Filed Against Cancer Genetics, Inc. – CGIX” on May 31, 2018. Also published the news titled: “Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against …” on May 29, 2018.‘s news article titled: “Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer” with publication date: June 12, 2018 was also an interesting one.

Cancer Genetics, Inc. (NASDAQ:CGIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: